Navigation Links
Group Therapy: New approach to psychosis treatment could target multiple nervous system receptors
Date:2/1/2013

Philadelphia, Pa. Antipsychotic drugs, used in the treatment of psychotic disorders involving severe delusions and hallucinations, have been studied for more than 70 years. Currently available antipsychotic drugs, however, only alleviate certain symptoms, with results that vary greatly from patient to patient and frequently cause significant side effects.

A new understanding of how the brain's G-protein receptors work may soon enable a way to better customize and target antipsychotic drugs to treat specific symptoms. Researchers from Virginia Commonwealth University (VCU) will present their findings at the 57th Annual Meeting of the Biophysical Society (BPS), held Feb. 2-6, 2013, in Philadelphia, Pa.

G-protein coupled receptors (GPCRs) are responsible for activating so-called "G-proteins," internal signaling messengers that control the activity of many other internal proteins. The starring role of GPCRs in regulating a cell's activity makes them a leading pharmaceutical target: approximately 50 percent of the antipsychotic drugs produced are aimed at these important nervous system receptors.

A specific GPCR is integral to each of three key pathways for intercellular signaling, one for each of the chemical messengers dopamine, serotonin, and glutamate. But these individual GPCRs also form complexes with each other, altering their effects on signaling in the brain. The VCU team has focused on how GPCR complexes influence signaling in a distinct way from how individual GPCRs operate.

"The realization that receptors in the brain that bind and interpret dopamine, serotonin, and glutamate neurotransmitters form complexes with one another that signal very differently than when these receptors are found in isolation, promises to change the way we approach treatment of psychosis," explains VCU Ph.D. candidate Jason Younkin, who will present the team's findings.

Instead of targeting one neurotransmitter pathway at a time, Younkin and colleagues plan to target two or more at the same time. Antipsychotic drugs that target the complexes formed by the individual GPCRs will allow use of the signaling differences and could lead to more effective therapies.

"By understanding how receptor complexes signal and learning how to control these signals, it should enable the development of specific antipsychotic drugs that lack the many side effects that exist today," says VCU professor Diomedes E. Logothetis, a co-author of the study.


'/>"/>

Contact: Ellen R. Weiss
eweiss@biophysics.org
240-290-5606
American Institute of Physics
Source:Eurekalert

Related medicine news :

1. Fish Like Grouper, Barracuda May Pose Food-Poisoning Risk
2. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
3. US Drug Watchdog Now Urges Family Members Of Diabetics Who Used the Diabetes Drug Actos and Then Were Diagnosed with Bladder Cancer to Call The Johnson Law Group ASAP
4. Cunningham Financial Group Encourages Women to Celebrate “Cervical Health Awareness Month” by Following Important Health Tips
5. US Drug Watchdog is Now Urging Bladder Cancer Victims to Call the Johnson Law Group if They Used Diabetes Drug Called Actos Prior to Diagnosis
6. Dr. Andy Chiou elected President and Chief Executive Officer of Peoria Surgical Group, Ltd.
7. Ob/Gyn Group Urges Docs to Help Prevent Octomom-Type Multiple Births
8. The Boston Eye Group Implants First Intraocular Pressure Transducer for Glaucoma Monitoring
9. US Drug Watchdog Now Urges Users of Yaz Yasmin Birth Control Pills That Had a Stroke Or Developed Other Serious Medical Conditions to Contact The Johnson Law Group
10. Acceleration Fitness Center Now Offering Group Training Programs for Middle and High School Athletes
11. US Drug Watchdog Now Urges Families Of Diabetics Who Used The Diabetes Drug Actos, Developed Bladder Cancer and Died To Call The Johnson Law Group-For A Legal Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California ... Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended ... and healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology: